SSA
RLMD icon

Schonfeld Strategic Advisors’s Relmada Therapeutics RLMD Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,247
Closed -$162K – 2941
2026
Q1 		$162K Buy
23,247
+10,031
+76% +$47.5K ﹤0.01% 1797
2025
Q4 		$63.8K Buy
+13,216
New +$44.3K ﹤0.01% 1866
2023
Q4 		– Sell
-109,310
Closed -$328K – 2163
2023
Q3 		$328K Buy
+109,310
New +$325K ﹤0.01% 1312
2023
Q1 		– Sell
-75,300
Closed -$263K – 2562
2022
Q4 		$263K Sell
75,300
-75,200
-50% -$660K ﹤0.01% 1856
2022
Q3 		$5.57M Buy
+150,500
New +$4.17M 0.05% 492
2022
Q1 		– Sell
-54,800
Closed -$1.24M – 2875
2021
Q4 		$1.24M Sell
54,800
-58,138
-51% -$1.29M 0.01% 837
2021
Q3 		$2.96M Buy
112,938
+55,177
+96% +$1.48M 0.03% 578
2021
Q2 		$1.85M Buy
57,761
+3,260
+6% +$113K 0.02% 740
2021
Q1 		$1.92M Buy
+54,501
New +$1.91M 0.02% 675

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Schonfeld Strategic Advisors's RLMD Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 23,247 shares — an estimated $162K sold.

Schonfeld Strategic Advisors first reported a position in RLMD in Q1 2021 and held it in 9 quarters. The position peaked at $5.57M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 23,247 Relmada Therapeutics shares in Q2 2026, an estimated $162K.
  • Schonfeld Strategic Advisors first reported a position in Relmada Therapeutics in Q1 2021 and held it in 9 quarters.
  • Schonfeld Strategic Advisors's Relmada Therapeutics position peaked at $5.57M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.